格隆汇7月3日丨基石药业-B(02616.HK)发布公告,公司首次披露两款自主研发、针对自身免疫/炎症性疾病的双特异性抗体药物靶点:CS2013(B细胞激活因子[BAFF]/ 增殖诱导配体[APRIL]);和CS2015(OX40配体[OX40L]/ 胸腺基质淋巴细胞生成素[TSLP])。这两款药物具备同类最佳/同类首创潜力,目前均处于临床前候选化合物(PCC)确认阶段,临床前研究数据将在相关国际...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.